false
0001760542
0001760542
2024-01-25
2024-01-25
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January
25, 2024
HOOKIPA PHARMA INC.
(Exact name of Registrant as Specified in Its Charter)
| Delaware |
|
001-38869 |
|
81-5395687 |
(State
or Other Jurisdiction of
Incorporation) |
|
(Commission
File Number) |
|
(IRS
Employer
Identification No.) |
350
Fifth Avenue, 72nd Floor,
Suite 7240 |
|
|
| New York, New York |
|
10118 |
| (Address
of principal executive offices) |
|
(zip code) |
Registrant’s telephone number, including
area code: +43 1
890 63 60
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instructions A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of
the Act:
| Title of each
class |
Trading
Symbol(s) |
Name
of exchange on which registered |
| Common stock, $0.0001 |
HOOK |
The Nasdaq Global Select Market |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 1.02 Termination of a Material Definitive
Agreement.
On January 25, 2024, HOOKIPA Pharma
Inc. (“HOOKIPA”) received written notice (the “Notice”) from F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche
Inc. (collectively referred to as “Roche”) of their decision to terminate the Research Collaboration and License Agreement
(the “Collaboration Agreement”) among Roche and Hookipa Biotech GmbH (“HOOKIPA GmbH,” and together with HOOKIPA,
the “Company”), a wholly-owned subsidiary of HOOKIPA, dated October 18, 2022. Roche’s decision to terminate
the Collaboration Agreement was made according to Roche’s right to terminate without cause, acknowledging that, to date, HOOKIPA met all
go-forward criteria under the Collaboration Agreement.
The
Collaboration Agreement was entered into to (i) grant Roche an exclusive license to research, develop, manufacture and commercialize
the Company's pre-clinical HB-700 cancer program, an arenaviral immunotherapeutic for KRAS-mutated cancers, and (ii) grant Roche an option
right to exclusively license for research, development manufacturing and commercialization, a second, novel arenaviral immunotherapeutic
program targeting undisclosed cancer antigens.
Pursuant to the terms of the Collaboration
Agreement and the Notice, the Collaboration Agreement will be terminated on April 25, 2024. The Company remains eligible for a final milestone payment associated with an IND submission. Effective
April 25, 2024, the Company will regain full control of the associated intellectual property portfolio and will have full collaboration
and licensing rights for the HB-700 program. After the termination of the Collaboration Agreement, and except as disclosed above, there
is no other material relationship between the Company and Roche.
Item 2.02 Results
of Operations and Financial Condition.
On January 29, 2024, HOOKIPA issued
a press release which contained information regarding its preliminary, unaudited estimate of cash and cash equivalents and restricted
cash of approximately $117.5 million as of December 31, 2023. This information is preliminary and unaudited. Accordingly, undue
reliance should not be placed on such preliminary numbers. The Company expects to report its audited cash, cash equivalents and marketable
securities, as well as other information necessary for a complete understanding of its financial position, in its Annual Report on Form 10-K
for the fiscal year ended December 31, 2023.
The information in this Item 2.02 is intended
to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the
“Exchange Act”) or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another
filing under the Exchange Act or the Securities Act of 1933, as amended (the “Securities Act”), if such subsequent filing
specifically references the information furnished pursuant to Item 7.01 and Exhibit 99.1 of this Current Report on Form 8-K.
Item 2.05 Costs
Associated with Exit or Disposal Activities.
On January 29, 2024, HOOKIPA announced
its decision to prioritize clinical development of HB-200 for the treatment of HPV16+ head and neck cancers and Gilead-partnered programs
in infectious disease and to pause development activities related to HB-300 and most of its preclinical research activities. In connection
with this strategic refocus, on January 22, 2024, HOOKIPA’s board of directors approved a plan to reduce the Company’s
workforce by 55 full-time employees, or approximately 30% of the Company’s then-current employee base and to rebalance the Company’s
cost structure in alignment with the new prioritization of R&D programs (together, the “Reduction Plan”), and the Company
notified affected employees on January 29, 2024. HOOKIPA expects to implement and substantially complete the Reduction Plan during
the first quarter of 2024. In connection with the Reduction Plan, the affected employees will be provided severance benefits, including
cash severance payments. Each affected employee’s eligibility for these severance benefits is contingent upon such employee’s
entering into an effective separation agreement, which includes a general release of claims against the Company. The workforce reduction
is expected to result in approximately $1.5 million in severance, restructuring and related costs. HOOKIPA expects a non-cash impairment
of “assets under construction” between $10 million and $13 million from the discontinuation of the GMP facility project as
part of the Reduction Plan. The Company expects to recognize deferred upfront and milestone payments under the Collaboration Agreement
of approximately $20 million in connection with the termination by Roche.
The estimated charges that the Company expects
to incur in connection with this Reduction Plan are subject to a number of assumptions, and actual results may differ materially from
these estimates. The Company may also incur additional costs not currently contemplated due to events that may occur as a result of,
or that are associated with, the Reduction Plan.
Item 2.06 Material Impairments.
To the extent applicable, the information contained in Item 2.05 above
is incorporated into this Item 2.06 by reference.
Item 7.01 Regulation FD Disclosure.
On January 29, 2024, the Company issued a press release announcing
updates on the Company’s business priorities and oncology partnership programs. A copy of the press release is furnished hereto
as Exhibit 99.1.
The information in this Item 7.01 and Exhibit 99.1 attached hereto
is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise
subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or
the Exchange Act, except as expressly set forth by specific reference in such filing.
Forward Looking Statements
This Current Report on Form 8-K and other related materials may
contain a number of “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995,
as amended, including statements regarding HOOKIPA’s expectation about any or all of the following: (i) the timing and consequences
regarding the termination of the Collaboration Agreement, (ii) the extent, timing and plan of, and the costs and estimated cash
expenditures from, the Reduction Plan, and (iii) expected cash and cash equivalents as of December 31, 2023. Forward-looking
statements can be identified by terms such as “will,” “intent,” “expects,” “plans,” “potential,”
“would” or similar expressions and the negative of those terms. HOOKIPA has based these forward-looking statements largely
on its current expectations and projections about future events and financial trends that it believes may affect its business, financial
condition and results of operations. Although HOOKIPA believes that such statements are based on reasonable assumptions, forward-looking
statements are neither promises nor guarantees and they are necessarily subject to a high degree of uncertainty and risk. Because forward-looking
statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond
HOOKIPA’s control, you should not rely on these forward-looking statements as predictions of future events. These risks and uncertainties
include, among others: outcomes of HOOKIPA’s planned clinical trials and studies may not be favorable; that one or more of HOOKIPA’s
product candidate programs will not proceed as planned for technical, scientific or commercial reasons; availability and timing of results
from preclinical studies and clinical trials; uncertainty about regulatory approval to conduct clinical trials or to market a products;
uncertainties regarding intellection property protection; and those risk and uncertainties described under the heading “Risk Factors”
in HOOKIPA’s Form 10-Q for the quarter ended September 30, 2023 filed with the U.S. Securities and Exchange Commission,
and in any other subsequent filings made by HOOKIPA with the U.S. Securities and Exchange Commission, which are available at www.sec.gov.
Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as
of the date they are made. HOOKIPA disclaims any obligation or undertaking to update or revise any forward-looking statements contained
in this Current Report on Form 8-K, other than to the extent required by law.
Item 9.01. Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
HOOKIPA Pharma Inc. |
| |
|
| Date: January 29, 2024 |
By: |
/s/ Joern Aldag |
| |
|
Joern Aldag |
| |
|
Chief Executive Officer |
| |
|
(Principal Executive Officer) |
Exhibit 99.1
HOOKIPA Pharma Provides Update on Business Priorities
and Oncology Partnership Programs
| · | HOOKIPA to prioritize clinical development of HB-200
for the treatment of HPV16+ head and neck cancers and Gilead-partnered programs in infectious disease |
| · | HOOKIPA will regain global development rights to
HB-700 program for KRAS-mutated cancers from Roche; HOOKIPA remains eligible for milestone payment associated with submission of Investigational
New Drug application |
| · | HOOKIPA will implement cost saving initiatives, including a reduction of
workforce by approximately 30 percent |
| · | HOOKIPA maintains a strong cash position of $117.5
million as of December 31, 20231 |
NEW YORK and VIENNA,
January 29, 2024 – HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics
based on its proprietary arenavirus platform, today announced that the Company will focus
its resources in two strategic areas: (1) prioritize the clinical development of a randomized
trial for its HB-200 program in human papillomavirus 16 positive (HPV16+) head and neck squamous cell carcinoma (HNSCC) and (2) its
two Gilead-partnered infectious disease cure programs for hepatitis B and human immunodeficiency virus.
In the first-line setting
HB-200, in combination with pembrolizumab, has demonstrated best-in-class antigen specific T cell activation and has doubled the historic
objective response rates of standard of care treatment alone. The totality of the HB-200 data presents a clear opportunity for HOOKIPA
to advance this program in a randomized trial starting in mid-2024.
“HOOKIPA
has a tremendous opportunity to transform treatment of multiple disease areas using an entirely new class of medicines,”
said Joern Aldag, Chief Executive Officer at HOOKIPA. “As we move forward with our randomized trial for HB-200 in combination with
pembrolizumab, we have made an important decision to focus our resources and pursue this opportunity in earnest. We will focus on clinical
delivery and execution so that we can help address a significant unmet need for patients with advanced HPV16+ head and neck cancer.”
The
Company also announced that it has received notification from Roche of their decision to terminate the collaboration and licensing agreement
for HOOKIPA’s HB-700 program in KRAS mutated cancers. To date, HOOKIPA has met all go-forward criteria under the agreement and remains
eligible for a final milestone payment associated with IND submission. Effective April 25, 2024,
HOOKIPA will regain full control of the associated intellectual property portfolio and have full collaboration and licensing rights for
this program. As part of its strategic refocus, HOOKIPA will pause development activities related to HB-300 and most of its preclinical
research activities.
HOOKIPA will reduce its
workforce by approximately 30 percent and rebalance its cost structure in alignment with the new prioritization of the Company’s
programs. HOOKIPA maintains a strong cash position of $117.5 million1 as of December 31, 2023, and believes that the planned
reductions will help to conserve resources and better align its organization in direct support of late stage clinical development efforts.
Pipeline
Update and Upcoming Catalysts
The
strategic priorities for HOOKIPA are to advance its clinical programs including HB-200 and its two Gilead-partnered infectious disease
programs. The Company is planning to submit an IND for HB-700 in the first quarter of 2024 and will begin searching for a collaboration
partner. At this time, the company will not pursue further preclinical programs into development and pause further development of its
HB-300 to conserve capital and ensure pipeline success and operational efficiency.
| Program |
Indication |
Upcoming
Catalysts |
| Oncology Programs |
| HB-200 |
HPV16+ HNSCC |
· Additional
first-line data for HB-200 in combination with pembrolizumab (1H 2024)
· Initiation
of randomized trial (mid-2024) |
| HB-700 |
KRAS |
· IND
submission (1Q 2024)
· Publication
of preclinical research (1H 2024)
· Search
for new collaboration partner |
| |
| Infectious Disease Programs: Gilead-Partnered |
| HB-400 |
HBV |
· Gilead-led:
Phase 1b actively enrolling
· Next
milestone: Phase 2 initiation (Timing TBD) |
| HB-500 |
HIV |
· Initiation
of Phase 1 trial
· First
patient dosed, milestone payment (1H 2024) |
| |
| Paused Programs |
| HB-300 |
Prostate Cancer |
· Paused and utilize capital to support HB-200 development |
| Preclinical |
Multiple targets |
1 Cash position as of December 31,
2023, is unaudited
About HOOKIPA
HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage
biopharmaceutical company focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which are designed
to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. HOOKIPA’s replicating and non-replicating
technologies are engineered to induce robust and durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies.
HOOKIPA’s pipeline includes its wholly owned investigational arenaviral immunotherapies targeting Human Papillomavirus 16-positive
cancers, KRAS-mutated cancers, and other unnamed indications. In addition, HOOKIPA aims to develop functional cures of HBV and HIV in
collaboration with Gilead.
Find out more about HOOKIPA online at www.hookipapharma.com.
Forward Looking Statements
This press
release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including,
without limitation, implied and express statements by HOOKIPA regarding: timing and consequences regarding the termination of the Roche
Collaboration Agreement, the extent, timing and plan of and the costs and estimated cash expenditures from, the reduction of workforce,
and expected cash and cash equivalents as of December 31, 2023. Forward-looking statements can be identified by terms such as “will,”
“believes,” “expects,” “plans,” “potential,” “would” or similar expressions
and the negative of those terms. Such forward-looking statements involve substantial risks and uncertainties that could cause HOOKIPA’s
research and clinical development programs, future results, performance or achievements to differ significantly from those expressed
or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug
development process, including HOOKIPA’s programs’ early stage of development, the process of designing and conducting preclinical
and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing
drug products, HOOKIPA’s ability to successfully establish, protect and defend its intellectual property, risks relating
to business interruptions resulting from public health crises, the impact of public health crises on the enrollment of patients and timing
of clinical results, and other matters that could affect the sufficiency of existing cash to fund operations. HOOKIPA undertakes
no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could
cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of
the company in general, see HOOKIPA’s annual report on Form 10-K for the period ended December 31, 2022, quarterly report
on Form 10-Q for the quarter ended September 30, 2023 and other important factors in HOOKIPA’s subsequent filings
with the Securities and Exchange Commission, which are available on the SEC’s website at www.sec.gov and HOOKIPA’s
website at http://hookipapharma.com/. In addition, any forward-looking statements represent HOOKIPA’s views
only as of today and should not be relied upon as representing its views as of any subsequent date. HOOKIPA explicitly disclaims any
obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy
of any such forward-looking statements.
Availability
of Other Information About HOOKIPA
Investors
and others should note that we announce material financial information to our investors using our investor relations website (https://ir.hookipapharma.com/),
SEC filings, press releases, public conference calls and webcasts. We use these channels, as well as social media, to communicate
with our members and the public about our company, our services and other issues. It is possible that the information we post on social
media could be deemed to be material information. Therefore, we encourage investors, the media, and others interested in our company
to review the information we post on the U.S. social media channels listed on our investor relations website.
For further information, please contact:
Investors and Media
Michael Kaiser
michael.kaiser@hookipapharma.com
+ 1 (917) 984 7537
v3.24.0.1
Cover
|
Jan. 25, 2024 |
| Cover [Abstract] |
|
| Document Type |
8-K
|
| Amendment Flag |
false
|
| Document Period End Date |
Jan. 25, 2024
|
| Entity File Number |
001-38869
|
| Entity Registrant Name |
HOOKIPA PHARMA INC.
|
| Entity Central Index Key |
0001760542
|
| Entity Tax Identification Number |
81-5395687
|
| Entity Incorporation, State or Country Code |
DE
|
| Entity Address, Address Line One |
350
Fifth Avenue, 72nd Floor,
|
| Entity Address, Address Line Two |
Suite 7240
|
| Entity Address, City or Town |
New York
|
| Entity Address, State or Province |
NY
|
| Entity Address, Postal Zip Code |
10118
|
| City Area Code |
+43
|
| Local Phone Number |
1
890 63 60
|
| Written Communications |
false
|
| Soliciting Material |
false
|
| Pre-commencement Tender Offer |
false
|
| Pre-commencement Issuer Tender Offer |
false
|
| Title of 12(b) Security |
Common stock, $0.0001
|
| Trading Symbol |
HOOK
|
| Security Exchange Name |
NASDAQ
|
| Entity Emerging Growth Company |
true
|
| Elected Not To Use the Extended Transition Period |
true
|
| X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
| Name: |
dei_AmendmentFlag |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
| Name: |
dei_DocumentPeriodEndDate |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:dateItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
| Name: |
dei_DocumentType |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:submissionTypeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
| Name: |
dei_EntityAddressAddressLine1 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 2 such as Street or Suite number
| Name: |
dei_EntityAddressAddressLine2 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- Definition
+ References
+ Details
| Name: |
dei_EntityAddressCityOrTown |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCode for the postal or zip code
| Name: |
dei_EntityAddressPostalZipCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the state or province.
| Name: |
dei_EntityAddressStateOrProvince |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:stateOrProvinceItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityCentralIndexKey |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:centralIndexKeyItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionIndicate if registrant meets the emerging growth company criteria. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityEmergingGrowthCompany |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
| Name: |
dei_EntityFileNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:fileNumberItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
| Name: |
dei_EntityIncorporationStateCountryCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarStateCountryItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityRegistrantName |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityTaxIdentificationNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:employerIdItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionLocal phone number for entity.
| Name: |
dei_LocalPhoneNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
| Name: |
dei_PreCommencementIssuerTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
| Name: |
dei_PreCommencementTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTitle of a 12(b) registered security. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
| Name: |
dei_Security12bTitle |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:securityTitleItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the Exchange on which a security is registered. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
| Name: |
dei_SecurityExchangeName |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarExchangeCodeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Section 14a
-Number 240
-Subsection 12
| Name: |
dei_SolicitingMaterial |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
| Name: |
dei_TradingSymbol |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:tradingSymbolItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
| Name: |
dei_WrittenCommunications |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
Grafico Azioni HOOKIPA Pharma (NASDAQ:HOOK)
Storico
Da Dic 2024 a Gen 2025
Grafico Azioni HOOKIPA Pharma (NASDAQ:HOOK)
Storico
Da Gen 2024 a Gen 2025
